Episode Details
Back to Episodes
Jefferies London: Nanobiotix has a new platform that is meant to help RNA/DNA-based therapies, gene therapies, oncolytic viruses and other liver-delivered medicines have better efficacy
Published 9 months, 4 weeks ago
Description
CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal.